The company, founded in 2010 as a subsidiary of Synmosa Group, focuses on the development of inhalation products for lung diseases such as asthma. With a strong research and development team and state-of-the-art manufacturing facilities, Intech Biopharm is able to supply high-quality generic drugs and also challenge new drug combinations for obstructive airway diseases. In 2017, the company opened a dedicated manufacturing site to expand its product capacity and promote exports. Intech Biopharm is registered as an emerging stock and plans to go public in 2018, with a mission to provide innovative and high-quality products and services to patients and customers.